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Abstract
In the United States, breast cancer accounts for one in three cancer diagnoses in women, 
making it the most common type of cancer in women. One important chemotherapeutic 
agent used to treat breast cancer is doxorubicin, an anthracycline compound that causes 
cell death by damaging DNA in addition to producing reactive oxygen species. 
Previously, the Berdis lab developed an artificial nucleoside analog designated 5-NIdR 
that improves the efficacy of DNA damaging agents used against brain cancer. This 
nucleoside works by inhibiting the replication of damaged DNA created by certain 
chemotherapeutic agents. In this project, we tested the ability of 5-NIdR to increase the 
efficacy of doxorubicin in the treatment of breast cancer. This was accomplished by 
comparing the effects of doxorubicin in the absence and presence of 5-NIdR using 
MCF-7 breast cancer cells and non-cancerous fibroblasts as models. Our studies show 
that breast cancer cells are highly resistant to doxorubicin, displaying an LD50 value of 
840 nM which is 8-fold higher than that measured against non-cancerous fibroblasts 
(LD50 = 105 nM). Combining 5-NIdR with doxorubicin kills more cells compared to 
treatment with either doxorubicin or 5-NIdR used alone.
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